Thursday, March 9 at 1:00 PM EST
Please join Parent Project Muscular Dystrophy and Santhera Pharmaceuticals as we host a webinar Thursday, March 9 at 1:00 PM ET to discuss idebenone clinical trials in Duchenne.
Dr. Thomas Meier will present a history of the idebenone development program, discuss the need to address respiratory decline in Duchenne, explain the currently recruiting SIDEROS clinical trial of idebenone in boys using steroids, and leave time for discussion and fielding of questions.
- Kathi Kinnett
Senior Vice President of Clinical Care, Parent Project Muscular Dystrophy
- Jodi Wolff, PhD
Director – Patient Advocacy, Santhera Pharmaceuticals
- Thomas Meier, PhD
Chief Executive Officer, Santhera Pharmaceuticals
Thomas Meier was appointed Chief Executive Officer (CEO) of Santhera in October 2011, having served for 7 years as Chief Scientific Officer (CSO) for the company. Thomas was the founder and CEO of MyoContract, a Basel, Switzerland-based research company focused on orphan neuromuscular diseases, which he merged with Graffinity Pharmaceuticals of Heidelberg, Germany, in 2004, to form today’s Santhera. Thomas received his PhD in biology from the University of Basel in 1992 and subsequently joined the University of Colorado Health Sciences Center in Denver, CO. He has a distinguished scientific track record in the field of neuromuscular research.
- Visit ReadyTalk.com and use access code 9449985. (Be sure to test your computer beforehand)
- Audio Dial-In Information:
- U.S. & Canada: Dial 1.866.740.1260 and use the Access Code 9449985
- Outside the U.S. and Canada: Lookup your number
Please submit questions in advance to firstname.lastname@example.org, with “Santhera Webinar” in the subject line by Tuesday, March 7th at 12pm eastern.